| 摘要 |
The invention relates to glucagon-like peptide-1 (GLP-1). The invention also relates to the use of glucagon-like peptide-1 for treating obesity, stroke, myocardial infarction, catabolic changes after surgery, or irritable bowel syndrome. The invention also relates to the use of glucagon-like peptide-1 for the preparation of a medicament for the treatment of obesity, stroke, myocardial infarction, catabolic changes after surgery, or irritable bowel syndrome. |
